Navin Fluorine International Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Record margins, campaign-driven top-line dip: EBITDA margin surged 930 bps YoY to 28%, but revenue fell 6% QoQ as Specialty Chemicals ran a lighter campaign schedule. Management calls the revenue move purely timing-driven and points to a solid order book for the coming quarters.
• R32 commercialization is the star: The new R32 plant, commissioned in March 2025, is running at optimal capacity into a firm pricing environment, contributing roughly one-third of the margin expansion. The company is now firming up plans with partners to expand further.
• A wave of new products is about to hit: Three new specialty molecules, two new fluoro intermediates for an AI application, and a new Nectar molecule all begin supplies in Q2. The Chemours advanced materials partnership and the AHF project are on track for FY '27 and late Q2 FY '26 completion, respectively.
• The balance sheet is shifting into deployment mode: The capex frame has been expanded to INR700–1,000 crores, with the AHF plant, cGMP4 Phase 1, and the fluoro specialty project all moving toward commercialization over the next two to three quarters.
• What to watch next quarter: The revenue conversion from the Q2 new product launches, any firm commitment on the next R32 expansion, and whether the Agchem pricing pressure begins to ease as volumes recover.

R32: The Margin Engine Firing on All Cylinders

• Plant running flat out: The R32 project was successfully commercialized in March 2025 and is already operating at optimal capacity, with the Q1 run rate seen as sustainable for the remaining quarters.
• Pricing environment is a tailwind: The pricing landscape for refrigerant gases remains firm, and this strength was a material contributor to the margin improvement. Management declined to speculate on future pricing but emphasized its philosophy of placing product for value across geographies.
• Expansion plans taking shape: Management is firming up plans with international partners to further capitalize on the R32 opportunity given accelerating global demand. It will only commit to the right project for the right value and will stake a claim to entitlement when discussions with large customers are more advanced. No specific capacity figure or timeline was confirmed.
• Capex comparison clarified: Both R32 plants were built in the same capex range; no conversion of existing assets was done, as the prior asset base was fully shut down. Management pushed back firmly on an analyst's assertion that the earlier expansion was cheaper.

Vishad Mafatlal: "Given the accelerating global demand for R32, we are firming up our plans with international partners to further capitalize on this opportunity."

Specialty Chemicals: A Campaign-Driven Dip, Not a Demand Problem

• Revenue decline is a scheduling artifact: Specialty Chemicals revenue fell from INR259 crores to INR219 crores QoQ because production is campaign-driven. Utilization at the Dahej plant dropped from 80–85% to approximately 70%, and management explicitly warned against reading anything beyond campaign timing into the move.
• Three new molecules begin in Q2: Supplies for three new molecules commence in Q2 FY '26. Two of these are fluoro intermediates for a global partner's new innovative AI application, and both have large enough potential to warrant future investment. A third fluoro molecule also begins delivery next quarter.
• Fluoro specialty project to contribute this year: The Dahej fluoro specialty project, launched in December 2024, is expected to deliver a meaningful contribution this year. Management is reasonably confident of hitting the full PAR of the INR540 crores plant by FY '27, with roughly half of that PAR arriving materially in FY '26.
• Agchem recovery is volume-led, not price-led: The inventory destocking issue is long gone, and volume recoveries are visible in the second half. However, intense Chinese competition continues to weigh on pricing, leaving the overall conversation flattish to slightly up.

Anish Ganatra: "The inventory stocking issue is long gone. I think the Chinese intense competition, which we've talked about before, continues to remain, pressure on pricing remains, volume recoveries in the second half, we are definitely seeing that come through."

CDMO (Navin Molecular): Building Toward the FY '27 Aspiration

• Strong order book and revenue visibility: The CDMO division delivered good results with robust revenue visibility backed by a solid order book for FY '26. The company has progressed toward the aspirational target set for FY '27.
• cGMP4 Phase 1 on track for Q3 FY '26: The Phase 1 expansion is progressing as planned, with commercialization expected in Q3 FY '26. Orders from Fermion are in hand, and the asset has built-in flexibility to manage unforeseeable events.
• Phase 2 trigger is customer-dependent: The INR128 crores Phase 2 capex will be triggered as soon as there is greater visibility on any customer. Currently, there is a high possibility linked to an EU major's product, but it remains early days. Management's philosophy is to trigger the next investment when utilization hits 60% or more.
• New late-stage molecule win: A scale-up order was received for another late-stage molecule with an EU pharma major, with supply commencing in Q2 FY '26. A European MSA molecule also received U.S. and European regulatory approval for label extension.
• Molecule mix strategy: The company will maintain a balance between early-stage and late-stage molecules, as early-stage work becomes the future commercial pipeline. Therapy areas were not specified; management emphasized capabilities in complex chemistries and synthesis.

Anish Ganatra: "Our idea about the CDMO business is actually to make sure that whenever the capacity utilization of the plant hits 60% or more, it start triggering the cost for the next capex investment because you're always going to need that sort of headroom to continue to grow."

Advanced Materials & AHF: The Next Leg of the Story

• AHF project nearing completion: The AHF project is advancing steadily with a completion target of end of Q2 FY '26. Some merchant sales will begin this year, with the focus squarely on the electronic space rather than solar.
• Value-over-volume strategy for AHF: The plant is set up for long-term requirements, not near-term utilization. The strategy is to maximize value per kg of HF rather than chase volume. Management declined to share specific realization or margin comparisons versus current HF.
• Electronic-grade HF as a stepping stone: The exclusive tie-up with Buss ChemTech AG Switzerland for electronic-grade HF is a starting point. Other products are in development and pilot stages for data center and semiconductor applications, including photoresist-type chemistries.
• Chemours partnership on track: The strategic partnership with Chemours to manufacture Opteon, a two-phase immersion cooling fluid for data centers, is under execution with commercial production targeted for Q1 FY '27. Ramp-up to optimum utilization is expected to be quick given the small capacity. Management declined to discuss revenue potential or asset turns under the commercial arrangement.

Anish Ganatra: "The ultimate game is to not leave the prize on the..."

Nectar & Legacy: Steady Contribution, Customer-Led Sequencing

• Firm orders for the dedicated capacity: The anchor customer has placed firm orders for the remainder of the year, representing 100% of the dedicated capacity, which is 50% of the overall Nectar capacity.
• Customer-driven product sequencing: The customer asked Navin to prioritize a new molecule earlier than planned. The company is already under modification to make that product, with deliveries starting within Q2. It will revert to the original molecule toward the end of the year.
• Ramp-up trajectory: Half of the dedicated capacity PAR will be delivered this year (FY '26), with full PAR achieved by FY '27. The ballpark revenue number discussed by the analyst was not explicitly confirmed by management.

Margin Walk & Capital Allocation

• The 930 bps margin bridge: Two-thirds of the YoY margin improvement came from operating leverage, with the remaining one-third from pricing and the environment, notably the strong R32 refrigerant gas pricing.
• No revised margin guidance yet: When asked whether the 25% margin guidance for FY '26 would be revisited given the current 28% level, management offered no binary answer. The team is continuing its efforts on operating leverage and efficiency.
• Capex frame expanded: The capex envelope has been widened to INR700–1,000 crores while maintaining solid financial ratios and balance sheet flexibility. Whether this includes pharma expansion or is largely specialty and other areas was not addressed in the call.

Anish Ganatra: "If you look how that growth has come through, 2/3 of that has come through operating leverage and 1/3 has come through pricing and environment, what one may call as that."

Guidance & Commitments

Key Metrics